A six week, multicenter, double blind, double-dummy, parallel, comparative study to compare the efficacy, safety and tolerability of ziprasidone with risperidone in the treatment of Chinese subjects with acute exacerbation of schizophrenia

Trial Profile

A six week, multicenter, double blind, double-dummy, parallel, comparative study to compare the efficacy, safety and tolerability of ziprasidone with risperidone in the treatment of Chinese subjects with acute exacerbation of schizophrenia

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Apr 2015

At a glance

  • Drugs Risperidone; Ziprasidone
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 03 May 2008 Results presented at APA 2008.
    • 14 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top